Fenofibrate inhibits reactive amyloidosis in mice.
OBJECTIVE
To examine the effects of the lipid-lowering agent fenofibrate on experimental AA amyloidosis and on serum amyloid A (SAA) levels.


METHODS
Fenofibrate was administered orally in a mouse model of amyloidosis, which is induced by injections of amyloid-enhancing factor and Freund's complete adjuvant. Fenofibrate was given for 3 weeks, including a 1-week course before induction of amyloidosis. Splenic amyloid deposits were evaluated histologically, and SAA levels were measured.


RESULTS
Fenofibrate inhibited the formation of splenic amyloid deposits and suppressed the elevation of SAA levels. CONCLUSION; Fenofibrate inhibits experimental amyloidosis by reducing levels of the precursor SAA.
Murai
Takehiro
T
Niigata University School of Medicine, Asahimachi 1-757, Niigata 951-8510, Japan.
Yamada
Toshiyuki
T
Miida
Takashi
T
Arai
Katsumitsu
K
Endo
Naoto
N
Hanyu
Tadamasa
T
D000209:Acute-Phase Proteins / Q000378:metabolism; D000686:Amyloidosis / Q000097:blood / Q000188:drug therapy*; D000818:Animals; D005260:Female; D011345:Fenofibrate / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D015850:Interleukin-6 / Q000097:blood; D051379:Mice; D008808:Mice, Inbred CBA; D000685:Serum Amyloid A Protein / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D000209:Acute-Phase Proteins; D000960:Hypolipidemic Agents; D015850:Interleukin-6; D000685:Serum Amyloid A Protein; D014280:Triglycerides; D011345:Fenofibrate